David E. Lazar's most recent trade in Sow Good Inc was a trade of 1,500,000 Series AA Preferred Stock done . Disclosure was reported to the exchange on Dec. 31, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Sow Good Inc | David Elliot Lazar | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Dec 2025 | 1,500,000 | 1,500,000 | - | - | Series AA Preferred Stock | |
| Kala Pharma Inc | David Elliot Lazar | Director, Chief Executive Officer | Other type of transaction at price $ 0.00 per share. | 18 Dec 2025 | 368,614 | 0 | - | - | Convertible Loan | |
| Kala Pharma Inc | David Elliot Lazar | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Nov 2025 | 900,000 | 900,000 | - | - | Series AA Convertible Preferred Stock | |
| Cyclacel Pharma Inc | David Elliot Lazar | Ten Percent Owner | Sale of securities on an exchange or to another person at price $ 12.36 per share. | 30 Jul 2025 | 6,750 | 155,838 (0%) | 0% | 12.4 | 83,430 | Common Stock |
| Cyclacel Pharma Inc | David Elliot Lazar | Interim CEO, Ten Percent Owner | Sale of securities on an exchange or to another person at price $ 0.03 per share. | 26 Feb 2025 | 194,628,820 | 0 (0%) | 1131% | 0.0 | 5,507,996 | Common Stock |
| Cyclacel Pharma Inc | David Elliot Lazar | Interim CEO, Ten Percent Owner | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Feb 2025 | 191,978,820 | 194,628,820 (999.99%) | 1116% | - | Common Stock | |
| Cyclacel Pharma Inc | David Elliot Lazar | Interim CEO, Ten Percent Owner | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Feb 2025 | 2,650,000 | 2,650,000 (15%) | 15% | - | Common Stock | |
| Cyclacel Pharma Inc | David Elliot Lazar | Interim CEO, Ten Percent Owner | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Feb 2025 | 1,745,262 | 354,738 | - | - | Series D Convertible Preferred Stock | |
| Cyclacel Pharma Inc | David Elliot Lazar | Interim CEO, Ten Percent Owner | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Feb 2025 | 1,000,000 | 0 | - | - | Series C Convertible Preferred Stock | |
| Minim Inc | David E. Lazar | Director, Ten Percent Owner | Sale of securities on an exchange or to another person at price $ 0.00 per share. | 18 Feb 2025 | 2,800,000 | 0 | - | - | Warrants | |
| Minim Inc | David E. Lazar | Director, Ten Percent Owner | Sale of securities on an exchange or to another person at price $ 0.00 per share. | 18 Feb 2025 | 2,219,447 | 85,910 | - | - | Series A Convertible Preferred Stock | |
| Minim Inc | David E. Lazar | Director, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Feb 2025 | 1,200,000 | 2,681,980 | - | - | Common Stock | |
| Cyclacel Pharma Inc | David Elliot Lazar | Interim CEO, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Feb 2025 | 2,100,000 | 2,100,000 | - | - | Series D Convertible Preferred Stock | |
| Minim Inc | David E. Lazar | Director, Ten Percent Owner | 26 Dec 2024 | 1,456,980 | 1,481,980 | - | 0.0 | 49,974 | Common Stock | |
| LQR House Inc | David E. Lazar | Director, President | 21 Nov 2024 | 821,818 | 280,000 | - | - | Common Stock | ||
| LQR House Inc | David E. Lazar | Director, President | 21 Nov 2024 | 280,000 | 0 | - | - | Common Stock | ||
| Minim Inc | David E. Lazar | Director, Ten Percent Owner | 21 Oct 2024 | 305,357 | 2,305,357 | - | - | Series A Convertible Preferred Stock | ||
| Opgen Inc | David E. Lazar | Director, Chief Executive Officer, Ten Percent Owner | Sale of securities on an exchange or to another person at price $ 0.00 per share. | 30 Jul 2024 | 550,000 | 0 | - | - | Series E Convertible Preferred Stock | |
| Opgen Inc | David E. Lazar | Director, Chief Executive Officer, Ten Percent Owner | Purchase of securities on an exchange or from another person at price $ 0.00 per share. | 23 Apr 2024 | 150,000 | 550,000 | - | - | Series E Convertible Preferred Stock | |
| Opgen Inc | David E. Lazar | Director, Chief Executive Officer, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Apr 2024 | 150,000 | 550,000 | - | - | Series E Convertible Preferred Stock | |
| Opgen Inc | David E. Lazar | Director, Chief Executive Officer, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Apr 2024 | 100,000 | 100,000 (1%) | 1% | - | Common Stock | |
| Opgen Inc | David E. Lazar | Director, Chief Executive Officer, Ten Percent Owner | Purchase of securities on an exchange or from another person at price $ 0.00 per share. | 05 Apr 2024 | 200,000 | 9,600,000 | - | - | Series E Convertible Preferred Stock | |
| Opgen Inc | David E. Lazar | Director, Chief Executive Officer, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Apr 2024 | 200,000 | 200,000 | - | - | Series E Convertible Preferred Stock | |
| Minim Inc | David E. Lazar | Director, Ten Percent Owner | 29 Jan 2024 | 2,800,000 | 2,800,000 | - | - | Warrants | ||
| Minim Inc | Lazar E. David | Director, Ten Percent Owner | 29 Jan 2024 | 2,000,000 | 2,000,000 | - | - | Series A Convertible Preferred Stock | ||
| Minim Inc | David Lazar E. | Director | 22 Jan 2024 | 25,000 | 25,000 | - | - | Common Stock | ||
| Titan Pharma Inc (de) | David E. Lazar | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jul 2023 | 100,000 | 100,000 (0%) | 0% | 0 | Common Stock | |
| Titan Pharma Inc (de) | David E. Lazar | Director, Chief Executive Officer, Ten Percent Owner | Sale of securities on an exchange or to another person at price $ 1.23 per share. | 21 Jun 2023 | 3,388,902 | 0 (0%) | 4% | 1.2 | 4,168,349 | Common Stock, par value $0.001 |
| Titan Pharma Inc (de) | David E. Lazar | Director, Chief Executive Officer, Ten Percent Owner | Sale of securities on an exchange or to another person at price $ 1.23 per share. | 21 Jun 2023 | 359,066 | 0 (0%) | 0% | 1.2 | 441,651 | Common Stock, par value $0.001 |
| Titan Pharma Inc (de) | David E. Lazar | Director, Chief Executive Officer, Ten Percent Owner | Purchase of securities on an exchange or from another person at price $ 0.97 per share. | 24 Jan 2023 | 37,500 | 3,368,902 (4%) | 0% | 1.0 | 36,221 | Common Stock, par value $0.001 |
| Titan Pharma Inc (de) | David E. Lazar | Director, Chief Executive Officer, Ten Percent Owner | Purchase of securities on an exchange or from another person at price $ 1.00 per share. | 24 Jan 2023 | 20,000 | 3,388,902 (4%) | 0% | 1.0 | 20,066 | Common Stock, par value $0.001 |